Overview:
As the healthcare landscape continues to evolve, hospitals are put in a position to balance strategic patient care improvement initiatives, like decreasing false positive blood culture rates, while also measuring economic outcomes and the financial impact of these care initiatives. One challenge that hospitals and health systems encounter is the downstream negative effects of blood cultures. This is so widespread that it is difficult to capture and measure the clinical and economic impact while using their own internal data.
On account of this, Magnolia Medical Technologies partnered with a large, multi-hospital system in the Midwest and Cardamom. Cardamom brought their expertise in data, analytics, and EHR applications to conduct a system specific data analysis to identify the clinical and economic impact of false-positive blood cultures.
In this webinar, we review the findings and retrospective analysis completed at a large, multi-hospital system in the Midwest. We share how this particular study demonstrated the irrefutable impact, clinically and economically, of patients that received a false-positive blood culture result in comparison to patients who received a true-negative result.
Webinar Objectives:
- Understand the clinical and economic impact of false-positive blood culture results.
- Explore key findings from a system-specific data analysis conducted at a large Midwest hospital system.
- Learn how advanced data and EHR analytics can provide actionable insights to improve patient care and outcomes.
Speakers:
Anna Crum
Solutions Manager, Cardamom
Colleen Humphrey
Senior Manager, Magnolia Medical Technologies
